Glaxosmithkline Intellectual Property Development Limited

Glaxo Group Limited

Jiangsu Hengrui Medicine Company Ltd.

Shanghai Hengrui Pharmaceutical Co., Ltd.

Shanghai Institute of Pharmaceutical Industry

Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Xiaomin Zhang

Zehong Wan

Jian Wang

Eric Steven Manas

Vipulkumar Kantibhai Patel

Christopher E Neipp

Joseph E Pero

Matthew Robert Sender

Raphael Anthony Rivero

Kai Long

Feng He

Weikang Tao

Hongjiang Xu

Qiyue Hu

Krista B Goodman

Cheng Peng

Zhedong Yuan

Wei Song

Hua Ying

Yimin Hu

Xueyan Zhu

Yun Jin

Hubo Wang

Jinping Shi

Ling Zhang

Zhaolong Tong

Hui Fu

Haihua Yu

Sarah E Dowdell

Weimin Hu

Chaobaihui Ye

Jiakang Sun

Christopher Ernst Neipp

A fused pyridine ring derivative represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and a use thereof as a therapeutic agent, particularly, in preparation of drugs for preventing and/or treating HIV infection.

Fused pyridine ring derivative, preparation method therefor, and pharmaceutical use thereof

Murine, chimeric or humanized anti-Abeta antibody having a specific CDR region, an antigen-binding fragment thereof, a pharmaceutical composition thereof, and usage thereof. Use of a humanized anti-Abeta antibody for the preparation of drugs for the treatment of a disease or disorder (such as Alzheimer's disease) caused by amyloid beta protein.

Anti-Aβ antibodies and antigen-binding fragments thereof

The present invention relates to novel compounds that inhibit Lp-PLAactivity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA, for example Alzheimer's disease.

Compounds

The present invention relates to novel compounds that inhibit Lp-PLAactivity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA, for example atherosclerosis, Alzheimer's disease.

The present invention relates to novel 3,4-dihydro-1H-pyrimido[1,6-a]pyrimidin-6(2H)-one compounds that inhibit Lp-PLAactivity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA, for example atherosclerosis, Alzheimer's disease.

3,4-dihydro-1H-pyrimido[1,6-a]pyrimidin-6(2H)-one compounds and their therapeutic applications

[object Object]

The present invention relates to novel compounds that inhibit Lp-PLAactivity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.

Tricyclic compounds, preparation methods, and their uses

Disclosed are dihydroindolone compounds which can modulate the activity of protein tyrosine kinases, a method for preparing the same, and pharmaceutical compositions comprising the same. Also disclosed are use of such compounds and pharmaceutical compositions thereof in the treatment and/or prophylaxis of protein tyrosine kinase associated diseases in an organism, particularly in the treatment and/or prophylaxis of tumors and fibroblast proliferation associated diseases.

Dihydroindolinone derivatives

Growing community of inventors

Shanghai, China

Xiaomin Zhang